NexPoint Expands Life Sciences Real Estate Footprint with Acquisition of Two Properties from Adare Pharma Solutions
Properties were indirectly acquired by NexPoint Life Sciences II DST, a Delaware statutory trust seeking to raise $42 million in equity from accredited investors via a private placement offering DALLAS, May 17, 2023 /PRNewswire/ — NexPoint, a multibillion-dollar alternative investment platform, today announced the acquisition of two life sciences industrial properties located in Philadelphia, Pennsylvania, from Frontida Biopharm, LLC, a company in the […]
Featured Video: Focus on Alternatives: Real Estate Investing in Life Sciences
In an interview with ADISA board member Greg Mausz, Nexpoint’s chief financial officer and executive vice president of finance, Brian Mitts, provides insight on how life sciences investing functions in real estate. “So, it’s in pharmaceuticals and biotech, but it’s not the companies themselves, it’s in the real estate that they utilize,” said Mitts. Mitts […]
First Look: NexPoint Unveils Plans for Massive TxS Life Sciences District in Plano
The 200-acre project centered on the former headquarters of Electronic Data Systems could eventually offer over 4 million square feet of lab, office, and therapeutic production space—and “establish North Texas as a leader in life sciences,” according to NexPoint Founder James Dondero. BY LANCE MURRAY • FEB 7, 2023 Plans and renderings have been revealed for the […]
NexPoint Announces Proposal for TxS District, a 200-Acre Life Sciences District Centered at the Former EDS Campus in Plano, Texas
Proposed development would create a life science ecosystem with world-class lab, office, and therapeutic production space PLANO, Texas, Feb. 7, 2023 /PRNewswire/ — NexPoint, a multibillion-dollar alternative investment firm, announces plans for TxS District, a proposed 200-acre life sciences development in Plano, Texas. The project, named to signify “Technology x Science,” is designed to foster innovation and collaboration among […]
NexPoint Leads Series B Financing for Biotechnology Company Sapience Therapeutics
HARRISON, N.Y., May 31, 2022 /PRNewswire/ — Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today the completion of a $41 million Series B financing. The financing was led by new investor NexPoint and included participation from existing investors Bristol Myers Squibb, Eshelman […]
NexPoint Participates in Series C Financing for Apnimed, a Clinical-stage Pharmaceutical Company Focused on Treating Sleep Disorders
CAMBRIDGE, Mass. May 4, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today that it has raised $62.5 million of committed capital in a Series C financing. New investor, Sectoral Asset Management, led the round. Also participating were new investors […]
